Abstract
Purpose
We aimed to compare imaging with 123I-MIBG and 68Ga-DOTA-TATE in neural crest tumours (NCT) to see if the latter could offer more advantage in detecting extra lesions and have higher sensitivity for malignant lesions.
Procedures
We retrospectively reviewed 12 patients (M = 10, F = 2; age range 20–71 years) with NCT (phaeochromocytomas = 7, paragangliomas = 4, medullary thyroid cancer = 1) who underwent both 68Ga-DOTA-TATE positron emission tomography (PET) or PET/computed tomography (CT) and 123I-MIBG single-photon emission computed tomography within 6 months. Visual assessment of all lesions and measurement of target/non-target (T/N) ratio in selected lesions were performed. Five patients (aged 50 or less) had SDHB screening results correlated with imaging results of both radiopharmaceuticals. All patients had contrast-enhanced CT and/or other cross-sectional imaging.
Results
68Ga-DOTA-TATE PET showed tumour lesions in ten out of 12 patients with confirmed disease, while 123I-MIBG showed lesions in five out of 12 patients. In one patient, both 68Ga-DOTA-TATE PET and 123I-MIBG were negative, but CT, magnetic resonance imaging, and 2-deoxy-2-[18F]fluoro-D-glucose PET scans identified a lesion in the thorax. 68Ga-DOTA-TATE and 123I-MIBG detected a total of 30 lesions, of which 29/30 were positive with 68Ga-DOTA-TATE and 7/30 with 123I-MIBG. We also found higher incidence of SDHB positive results in patients with positive 68Ga-DOTA-TATE.
Conclusion
Our limited data suggest that 68Ga-DOTA-TATE is a better imaging agent for NCT and detects significantly more lesions with higher T/N ratio compared to 123I-MIBG. 68Ga-DOTA-TATE was more likely to detect malignant lesions as indicated by correlating imaging results with SDHB screening.
Similar content being viewed by others
References
Neumann HP, Bausch B, McWhinny SR, Bender BU, Gimm O, Franke G et al (2002) Germ-line mutations in nonsyndromic pheochromocytoma. N Engl J Med 346:1459–1466
O’Riordain D, Young WF, Grant CS, Carney JA, van Heerden (1996) Clinical spectrum and outcome of functional extraadrenal paraganglioma. World J Surg 20:916–922
Reisch N, Peczkowska M, Januszewicz A, Neumann HP (2006) Pheochromocytoma: presentation, diagnosis and treatment. J Hypertens 24:2331–2339
Win Z, Al-Nahhas A, Towey D, Todd JF, Rubello D, Lewington V, Gishen P (2007) 68Ga-DOTATATE PET in neuroectodermal tumours: first experience. Nucl Med Commun 28:359–363
Ilias I, Chen CC, Carrasquillo JA, Whatley M, Ling A, Lazurova I et al (2008) Comparison of 6-18F-fluorodopamine positron emission tomography to 123I-metaiodobenzylguanidine and 111In-pentetreotide scintigraphy in the localization of non-metastatic and metastatic pheochromocytoma. J Nucl Med 49:1613–1619
Lewigton VJ (2003) Targeted radionuclide therapy for neuroendocrine tumours. Endocr-Relat Cancer 10:497–501
Kwekkeboom DJ, Mueller-Brand J, Paganelli G, Anthony LB, Pauwels S, Kvols LK et al (2005) Overview of results of peptide receptor radionuclide therapy with 3 radiolabeled somatostatin analogs. J Nucl Med 46(Suppl 1):62S–66S
Smith SL, Vincent RM, Perkins AC, Wastie ML, Sokal M (2001) Does simple estimation of 131I-metaiodobenzylguanidine uptake in patients with neural crest tumours correlate with clinical outcome? Nucl Med Commun 22:257–260
Pasini B, Stratakis CA (2009) SDH mutations in tumorigenesis and inherited endocrine tumours: lesson from the phaeochromocytoma-paraganglioma syndromes. J Intern Med 266(1):19–42
Yankovskaya V, Horsefield R, Törnroth S, Luna-Chavez C, Miyoshi H, Léger C et al (2003) Architecture of succinate dehydrogenase and reactive oxygen species generation. Science 299:700–704
Astuti D, Latif F, Dallol A, Dahia PL, Douglas F, George E et al (2001) Gene mutations in the succinate dehydrogenase subunit SDHB cause susceptibility to familial pheochromocytoma and to familial paraganglioma. Am J Hum Genet 69:49–54
Baysal BE, Ferrell RE, Willett-Brozick JE, Lawrence EC, Myssiorek D, Bosch A et al (2000) Mutations in SDHD, a mitochondrial complex II gene, in hereditary paraganglioma. Science 287:848–851
Niemann S, Muller U (2000) Mutations in SDHC cause autosomal dominant paraganglioma, type 3. Nat Genet 26:268–270
Karagiannis A, Mikhailidis DP, Athyros VG, Harsoulis F (2007) Pheochromocytoma: an update on genetics and management. Endocr-Relat Cancer 14:935–956
Benn DE, Gimenez-Roqueplo A-P, Reilly JR, Bertherat J, Burgess J, Byth K et al (2006) Clinical presentation and penetrance of pheochromocytoma/paraganglioma syndromes. J Clin Endocrinol Metab 91:27–836
Klein RD, Jin L, Rumilla K, Young WF Jr, Lloyd RV (2008) Germline SDHB mutations are common in patients with apparently sporadic sympathetic paragangliomas. Diagn Mol Pathol 17(2):94–100
Bryant J, Farmer J, Kessler LJ, Townsend RR, Nathanson KL (2003) Pheochromocytoma: the expanding genetic differential diagnosis. J Natl Cancer Inst 95(16):1196–1204
Chrisoulidou A, Kaltsas G, Ilias I, Grossman AB (2007) The diagnosis and management of malignant phaeochromocytoma and paraganglioma. Endocr-Relat Cancer 14(3):569–585
Ilias I, Pacak K (2004) Current approaches and recommended algorithm for the diagnostic localization of pheochromocytoma. J Clin Endocrinol Metab 89:479–491
Go AS (1998) Refining probability: an introduction to the use of diagnostic tests. In: Friedland DJ (ed) Evidence-based medicine. McGraw-Hill, New York, pp 12–33
Wieland DM, Wu JL, Brown LE (1980) Radiolabelled adrenergic neuron blocking agents: adrenomedullary imaging with 131Iiodobenzylguanidine. J Nucl Med 21:349–353
Beierwaltes WH (1991) Endocrine imaging: parathyroid, adrenal cortex and medulla, and other endocrine tumors. Part II. J Nucl Med 32:1627–1639
McEwan AJ, Shapiro B, Sisson JC, Beierwaltes WH, Ackery DM (1985) Radioiodobezylguanidine for the scintigraphic location and therapy of adrenergic tumors. Semin Nucl Med 15:132–153
Shulkin BL, Ilias I, Sisson JC, Pacak K (2006) Current trends in functional imaging of pheochromocytomas and paragangliomas. Ann NY Acad Sci 1073:374–382
Mann GN, Link JM, Pham P, Pickett CA, Byrd DR, Kinahan PE et al (2006) 11C-metahydroxyephedrine and 18F-fluorodeoxyglucose positron emission tomography improve clinical decision making in suspected phaeochromocytoma. Ann Surg Oncol 13(2):187–197
Reynolds S, Lewington V (2008) Radionuclide imaging of phaeochromocytoma and paraganglioma. Imaging 34:21–24
Koopmans KP, Jager PL, Kema IP, Kerstens MN, Albersy F, Dullaart RPF (2008) 111In-octreotide is superior to 123I-metaiodobenzylguanidine for scintigraphic detection of head and neck paragangliomas. J Nucl Med 49:1232–1237
Ilias I, Pacak K (2008) A clinical overview of pheochromocytomas/paragangliomas and carcinoid tumors. Nucl Med Biol 35(Suppl 1):S27–S34
Brink I, Hoegerle S, Klisch J, Bley TA (2005) Imaging of pheochromocytoma and paraganglioma. Fam Cancer 4(1):61–68
Maurea S, Mainolfi C, Wang H, Varrella P, Panico MR, Klain M et al (1996) Positron emission tomography (PET) with fludeoxyglucose F 18 in the study of adrenal masses: comparison of benign and malignant lesions. Radiol Med 92:782–787
Shulkin BL, Thompson NW, Shapiro B, Francis IR, Sisson JC (1999) Pheochromocytomas: imaging with 2-[fluorine-18]fluoro-2-deoxy-D-glucose PET. Radiology 212:35–41
Neumann DR, Basile KE, Bravo EL, Chen EQ, Go RT (1996) Malignant phaeochromocytoma of the anterior mediastinum: PET findings with [18F] FDG and 82Rb. J Comput Assist Tomogr 20:312–316
Mamede M, Carrasquillo JA, Chen CC, Del Corral P, Whatley M, Ilias I et al (2006) Discordant localization of 2-[18F]-fluoro-2-deoxy-D-glucose in 6-[18F]-fluorodopamine- and [(123)I]-metaiodobenzylguanidine-negative metastatic pheochromocytoma sites. Nucl Med Commun 27:31–36
Timmers H, Chen C, Carrasquillo J, Whatley M, Ling A, Havekes B et al (2009) Comparison of 18F-fluoro-L-DOPA, 18F-fluoro-deoxyglucose, and 18F-fluorodopamine PET and 123I-MIBG scintigraphy in the localization of pheochromocytoma and paraganglioma. J Clin Endocrinol Metab 94(12):4757–4767
Khan S, Lloyd C, Szyszko T, Win Z, Rubello D, Al-Nahhas A (2008) PET imaging in endocrine tumours. Minerva Endocrinol 33(2):41–52
Al-Nahhas A, Win Z, Szyszko T, Singh A, Khan S, Rubello D (2007) What can gallium-68 PET add to receptor and molecular imaging? Eur J Nucl Med Mol Imaging 34(12):1897–1901
Conflict of Interest Statement
The authors declare they have no conflict of interest in the preparation of the present paper.
Author information
Authors and Affiliations
Corresponding author
Additional information
Significance: The data of the present study are consistent with a higher sensitivity of Ga-DOTA-TATE PET in comparison with 123-MIBG conventional scintigraphy in detecting tumoral deposits of metastatic malignant neural crest tumours. This may be related both to the higher spatial resolution of the PET system in comparison with conventional gamma camera imaging and to the investigation of a different metabolic pathway of these tumours: the somatostatin receptor density evaluated by Ga68-DOTA-TATE in comparison with the catechomaminergic behaviour of the tumoral cells evaluated by 123-MIBS scintigraphy.
Rights and permissions
About this article
Cite this article
Naji, M., Zhao, C., Welsh, S.J. et al. 68Ga-DOTA-TATE PET vs. 123I-MIBG in Identifying Malignant Neural Crest Tumours. Mol Imaging Biol 13, 769–775 (2011). https://doi.org/10.1007/s11307-010-0396-8
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11307-010-0396-8